Karyopharm Therapeutics Inc. (KPTI) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -22.73M | -11.83M | -5.86M | -18.7M | -38.98M | -25.81M | -19.45M | -38.5M | -43.73M | -18.59M | -29.53M | -25.7M |
| Operating CF Margin % | -64.81% | -34.71% | -13.3% | -49.29% | -129.88% | -84.51% | -50.16% | -89.98% | -132% | -55.07% | -82.01% | -68.38% |
| Operating CF Growth % | 41.7% | 54.17% | 69.88% | 51.43% | 10.84% | -38.88% | 34.12% | -49.81% | -131.23% | 30.76% | -4.09% | 26.88% |
| Net Income | -22.39M | -102.2M | -33.13M | -37.25M | -23.46M | -30.78M | -32.07M | 23.79M | -37.36M | -41.84M | -34.51M | -32.63M |
| Depreciation & Amortization | 12K | 2.46M | 121K | -42K | 78K | 2.44M | 2.49M | 91K | 293K | 294K | 285K | 274K |
| Stock-Based Compensation | 0 | 3.9M | 2.8M | 3.78M | 3.56M | 3.86M | 4.18M | 5.41M | 4.97M | 5.18M | 5.08M | 6.06M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -4.2M | 78.5M | 10.1M | 4.76M | -17.64M | -11.42M | -1.55M | -58.32M | 994K | 1.16M | -2.28M | -7.78M |
| Working Capital Changes | 3.85M | 5.5M | 14.25M | 10.05M | -1.52M | 10.08M | 7.49M | -9.47M | -12.62M | 16.62M | 1.89M | 8.38M |
| Change in Receivables | 2.82M | 5.7M | 1.05M | 2.31M | -4.48M | 1.01M | 6.22M | -6.91M | -4.12M | 10.96M | -5.64M | 2.92M |
| Change in Inventory | 439K | -72K | 1.03M | -223K | -30K | -67K | -1.2M | -707K | 274K | 62K | 567K | 155K |
| Change in Payables | 276K | -1.39M | 2.79M | -3.27M | 765K | 0 | 0 | -2.23M | 0 | 0 | 0 | 0 |
| Cash from Investing | 3.2M | 5M | 4.8M | 18.29M | 15.29M | 14.8M | 7.47M | 51.26M | 21.94M | 26.84M | -7.68M | 21.17M |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 53K | 0 | 0 | -195K | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | 0.17% | - | - | 0.59% | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 14.74M | 7.47M | 0 | 22.14M | 26.84M | -7.68M | 21.17M |
| Cash from Financing | 49.8M | 29.69M | 0 | 356K | 0 | 680K | 0 | 40.97M | 0 | 264K | 0 | 860K |
| Debt Issued (Net) | 0 | 20.54M | 0 | 0 | 0 | 0 | 0 | 40.19M | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 50.23M | 9.15M | 0 | 356K | 0 | 0 | 0 | 772K | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -431K | 0 | 0 | 0 | 0 | 680K | 0 | 0 | 0 | 264K | 0 | 860K |
| Net Change in Cash | 30.31M | 22.87M | -1.05M | -48K | -23.69M | -10.35M | -11.94M | 53.72M | -21.8M | 8.61M | -37.27M | -3.69M |
| Free Cash Flow | -22.73M | -11.83M | -5.86M | -18.7M | -38.98M | -25.76M | -19.45M | -38.5M | -43.92M | -18.59M | -29.53M | -25.7M |
| FCF Margin % | -64.81% | -34.71% | -13.3% | -49.29% | -129.88% | -84.33% | -50.16% | -89.98% | -132.58% | -55.07% | -82.01% | -68.38% |
| FCF Growth % | 41.7% | 54.08% | 69.88% | 51.43% | 11.24% | -38.59% | 34.12% | -49.81% | -132.26% | 30.56% | -3.95% | 26.88% |
| FCF per Share | -0.92 | -0.66 | -0.68 | -2.17 | -4.60 | -3.07 | -2.33 | -3.74 | -5.71 | -2.43 | -3.87 | -0.23 |
| FCF Conversion (FCF/Net Income) | 1.02x | 0.12x | 0.18x | 0.50x | 1.66x | 0.84x | 0.61x | -1.62x | 1.17x | 0.44x | 0.86x | 0.79x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 8.2M | 11.01M | 0 | 4.1M | 6.42M | 4.03M | 6.7M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |